Table 4

Comparison between factors and occurrence of adverse reactions, drug choice problems, and dosing problems
Factors Adverse reactions (n = 25) Frequency (Percentage, %) Drug choice problem (n = 76) Frequency (Percentage, %) Dosing problem (n = 55) Frequency (Percentage, %)
Yes No p-value Yes No p-value Yes No p-value
Elderly
Yes 11 (44.0) 74 (42.3) > 0.999a 28 (36.8) 87 (70.2) < 0.001a* 34 (61.8) 81 (70.4) 0.548a
No 14 (56.0) 101(57.7) 48 (63.2) 37 (29.8) 21 (38.2) 64 (29.6)
Polypharmacy
Yes 19 (76.0) 134 (76.6) > 0.999a 60 (78.9) 93 (75.0) 0.640a 38 (69.1) 115 (79.3) 0.182a
No 6 (26.0) 41 (23.4) 16 (21.1) 31 (25.0) 17 (30.9) 30 (20.7)
Duration of hospital stay
≤ 1 week 17 (68.0) 126 (72.0) 0.859a 45 (59.2) 98 (79.0) 0.004a* 40 (72.7) 103 (71.0) 0.951a
> 1 week 8 (32.0) 49 (28.0) 31 (40.8) 26 (21.0) 15 (27.3) 42 (29.0)
Microvascular complications
Yes 17 (68.0) 107 (61.1) 0.660a 53 (69.7) 71 (57.3) 0.106a 40 (72.7) 84 (57.9) 0.078a
No 8 (32.0) 68 (38.9) 23 (30.3) 53 (42.7) 15 (27.3) 61 (42.1)
Cardiovascular events
Yes 12 (48.0) 109 (62.3) 0.193b 47 (61.8) 74 (59.7) 0.877a 36 (65.5) 85 (58.6) 0.471a
No 13 (52.0) 66 (37.7) 29 (38.2) 50 (40.3) 19 (34.5) 60 (41.4)
Renal impairment
Yes 12 (48.0) 88 (50.3) > 0.999a 46 (60.5) 54 (43.5) 0.029a* 35 (63.6) 65 (44.8) 0.027a*
No 13 (52.0) 87 (49.7) 30 (39.5) 70 (56.5) 20 (36.4) 80 (55.2)
Liver impairment
Yes 1 (4.0) 10 (5.7) > 0.999b 6 (7.9) 5 (4.0) 0.399a 5 (9.1) 6 (4.1) 0.306a
No 24 (96.0) 165 (94.3) 70 (92.1) 119 (96.0) 50 (90.9) 139 (95.9)
Hyperlipidemia
Yes 7 (28.0) 57 (32.6) 0.819a 17 (22.4) 47 (37.9) 0.033a* 15 (27.3) 49 (33.8) 0.476a
No 18 (72.0) 118 (67.4) 59 (77.6) 77 (62.1) 40 (72.7) 96 (66.2)

a Computed using Continuity Correction; b Computed using Fisher’s Exact Test; * Statistically significant (p < 0.05).

Zaman Huri and Fun Wee

Zaman Huri and Fun Wee BMC Endocrine Disorders 2013 13:2   doi:10.1186/1472-6823-13-2

Open Data